


REVENUE
₹ 948 Crores
16%
EBITDA
₹ 190 Crores
32%
PAT
₹ 77 Crores
53%

Jubilant Life Sciences Limited (Formerly Jubilant Organosys Limited)
Regd. Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar - 244 223 (U.P.)

Unaudited Financial Results for the Quarter ended 30th June, 2011

[₹ in Lacs]

CONSOLIDATED RESULTS			Particulars	STANDALONE RESULTS		
Quarter Ended June 30 (Unaudited)		Year Ended March 31 (Audited)		Quarter Ended June 30 (Unaudited)		Year Ended March 31 (Audited)
2011	2010	2011		2011	2010	2011
94429	81762	343340	Net sales/Income from operations	61702	52031	220089
419	99	883	Other Operating Income	173	33	541
94848	81861	344223	Total income	61875	52064	220630
81204	72553	306812	Total expenditure	52207	42412	186069
(4201)	(2781)	(3880)	a) (Increase)/Decrease in stock in trade and work in progress	(2217)	(1835)	(3131)
6585	5763	24007	b) Purchase of traded goods	5504	4829	21637
33578	28201	112943	c) Raw & process materials consumed	28455	22337	90143
5872	5365	21188	d) Stores, spares, chemicals, catalyst & packing material consumed	2860	2227	9424
6001	5153	22404	e) Power & fuel	5544	4722	20665
1803	1438	6965	f) Other manufacturing expenses	1263	1014	4895
18976	17697	71842	g) Staff cost	4678	3799	17317
4977	4842	18010	h) Depreciation	2768	2393	9991
7613	6875	33333	i) Other Expenditure (Selling, general & admin. Expenses-Including Exchange Loss/Gain)	3352	2926	15128
13644	9308	37411	Operating profit before Other Income & Interest	9668	9652	34561
367	233	1296	Other Income	235	67	514
14011	9541	38707	Profit before Interest & Exceptional Items	9903	9719	35075
4338	1947	10506	Interest (Net)	3001	552	4625
9673	7594	28201	Profit after Interest but before Exceptional Items	6902	9167	30450
418	2080	4142	Exceptional items	268	1201	455
9255	5514	24059	Profit from Ordinary Activities before tax	6634	7966	29995
1516	578	1336	Tax Expenses (Net)	1245	1187	2032
7739	4936	22723	Net profit from Ordinary Activities after tax	5389	6779	27963
-	-	-	Extraordinary Items (net of tax expenses)	-	-	-
27	(107)	(249)	Minority Interest	-	-	-
7712	5043	22972	Net profit after Minority Interest	5389	6779	27963
1593	1588	1593	Paid-up share capital (Face value per share ₹ 1)	1593	1588	1593
		215634	Reserves (excluding revaluation reserve)			212466
4.84	3.17	14.42	Earnings per share before and after extraordinary items (Not annualized)	3.38	4.26	17.56
4.84	2.86	13.04	Basic (₹)	3.38	3.85	15.87
			Diluted (₹)			
			Public shareholding			
84129115	83627751	84129115	- Number of shares (₹ 1 each)	84129115	83627751	84129115
52.82	52.67	52.82	- Percentage of shareholding	52.82	52.67	52.82
			Promoters and promoter group Shareholding			
			a) Pledged/Encumbered			
7887333	14245000	7531333	- Number of shares	7887333	14245000	7531333
10.50	18.95	10.02	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	10.50	18.95	10.02
4.95	8.97	4.73	- Percentage of shares (as a % of the total share capital of the company)	4.95	8.97	4.73
			b) Non-Encumbered			
67264691	60907024	67620691	- Number of shares	67264691	60907024	67620691
89.50	81.05	89.98	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	89.50	81.05	89.98
42.23	38.36	42.45	- Percentage of shares (as a % of the total share capital of the company)	42.23	38.36	42.45

Notes:

- The Company has repaid during the quarter the Foreign Currency Convertible Bond 2011 amounting to US \$ 142.10 million along with premium on redemption US \$ 67.37 million.
- During the quarter one of our step down subsidiary where the Company holds 82.38% equity, Cadista Holdings Inc., USA (carrying on its generic business through a wholly owned subsidiary, Jubilant Cadista Pharmaceuticals Inc., USA), was required to file for registration with the Securities and Exchange Commission (SEC) of United States of America, under Section 12 (g) of the Securities and Exchange Control Act, United States of America, as the number of shareholders exceeded 500 as at March 31, 2011. The registration statement has been filed with SEC and was under review at the end of the quarter.
- The results for the corresponding quarter previous year are for the businesses remaining with the Company, post amalgamation/demerger, and has been restated to give effect to the Scheme of Amalgamation & Demerger (Scheme) approved by Hon'ble High Court of Judicature, Allahabad in FY 2011. Equity shares issued consequent upon Scheme and adjustment to FCCB conversion price on demerger has also been considered for recomputation of EPS for the corresponding quarter previous year.
- The Company's operates under one reportable segment viz. Pharmaceuticals and Life Sciences Products and Services (PLSPS).
- Exceptional items include :
 - Amortization of Foreign Currency Monetary Item Translation Difference Account-loss/(gain) ₹ 214 Lacs (Consolidated ₹ 214 Lacs).
 - Mark to Market in respect of unassigned forward contracts/Interest rate swap outstanding at the period end resulting in loss/(gain) amounting to ₹ 54 Lacs (Consolidated ₹ 204 Lacs).
- Tax Expenses (Net) is after considering the MAT Credit Entitlement.
- Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New -15, Disposals -15, Closing Balance - Nil.
- Previous year / periods figures have been regrouped/reclassified wherever necessary.
- The above un-audited results were, subjected to limited review by the auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 9th August, 2011.

For Jubilant Life Sciences Limited

Place : Noida

Date : 9th August, 2011

Shyam S Bhartia

Chairman & Managing Director

 visit us at www.jubl.com